Back to Results

The MINDS Study

Title Long-Term Nicotine Treatment of Mild Cognitive Impairment - the MIND study
Therapeutic Area Mild Cognitive Impairment
Principal Investigator Tinatin Chabrashvili, MD, PhD
Min Age 55 Years
Max Age 90 Years
Gender All
Contact Sarah Gans
(617) 636-7606
More Information


This is a phase 2, multi-center, randomized double-blind, placebo-controlled study to assess the efficacy and safety the nicotine patch to alleviate symptoms of mild cognitive impairment (MCI). Those who meet the study qualifications will be placed on either daily nicotine or placebo patches to be worn for 16 hours a day for the next 2 years accompanied by visits to the clinic. Participants must also have a study partner willing to participate who spends at least 10 hours a week with the participant. 

Study Details

Inclusion Criteria

  • Have subjective memory concerns reported by yourself, a doctor, or a close friend or family member.
  • On stable medication for 4 or more weeks (if any)
  • Has someone who is willing to accompany participant to most study visits and answer study questions about the participant. Study partner must spend 10 hours of more on average with study participant.

Exclusion Criteria

  • Any use of tobacco or nicotine products in the past year.
  • Any significant neurological disease such as Alzheimer's disease dementia, Parkinson's disease, seizure disorder, brain tumor, or history of head trauma.
  • History of alcohol or substance abuse in the past 2 years.

Study Requirements

Number of research visits: 10 
Length of participation: 2 years 
Number of blood collections: up to 6 
Number of lumbar punctures (optional): 2 
Number of MRIs (optional): 3